spacer
home > ict > summer 2020 > a golden opportunity… but not a silver bullet
PUBLICATIONS
International Clinical Trials

A Golden Opportunity… But Not a Silver Bullet


Once the domain of only the very largest pharmaceutical companies, functional service partnership (FSP) programmes are now also commonplace among small- and midsize companies. However, discussions surrounding FSP implementation often lack clarity of purpose, are poorly aligned with the sponsor’s development strategy, and are subject to design flaws that limit their effectiveness. As a result, the return on investment may be limited, and potential benefits can remain unrealised.

Sponsors who are considering adopting an FSP approach (or optimising existing FSPs) should carefully consider the following dimensions, which, though key, are often overlooked.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the Author

Barry Balfe is President of ICON Functional Services and leads the DOCS Functional Service Provision business with oversight of the Government and Public Health Solutions group. Barry has been with ICON for over 15 years and has held a number of senior roles, predominantly within the FSP space, where he has successfully grown this business and has developed and led a number of new strategic partnerships.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Stoelzle Glass Group division Pharma – Health & Safety expands its product portfolio with Type II glass

The company also introduces a newly developed, innovative, stable and environmental conscious process for the inner surface treatment of moulded Type III glass containers.
More info >>

White Papers
 
Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement